£2.2M award will be used to fund a Phase I/II clinical trial of Oxford Biomedica-102, an enhanced version of ProSavin®; a gene therapy for the treatment of Parkinson’s disease … Read More
Oxford, UK – 29 April 2014: Oxford BioMedica plc (LSE:OXB), (“the Company”) the leading gene based biopharmaceutical company, announces that it will regain the worldwide rights to RetinoStat… Read More
Click here to download the full 2013 Preliminary Results Statement.Click here to download the 2013 Results Presentation.Click here to… Read More
— Planned 21 patients dosed in “wet” age-related macular degeneration (wet AMD) US Phase I trial … Read More
Oxford, UK – 21 March 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present at the 2nd Annual Regen Med Investor Day to be held… Read More
— Oxford BioMedica regains worldwide rights to EncorStat® — — Sanofi broadens global rights to StarGen™ and UshStat® across all disease indications –… Read More
Oxford BioMedica Announces Publication of ProSavin® Phase I/II Study in The Lancet — Pioneering data published in world-leading, peer-reviewed medical journal —… Read More
Oxford, UK – 9 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that John Dawson, Chief Executive Officer, will present a company overview at the Biotech Showcase… Read More
Oxford, UK – 6 January 2014: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announced the results of its General Meeting held today in London. In accordance with Listing Rule 9.6.18, the… Read More
Oxford, UK – 18 December 2013: Oxford BioMedica plc (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, announces that it has signed an option agreement with GlaxoSmithKline (“GSK”) which grants GSK an option to a… Read More
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today announces that it has signed a £5 million secured loan facility agreement with its largest shareholder, the Vulpes… Read More
Oxford, UK – 19 November 2013: Oxford BioMedica (“Oxford BioMedica” or “the Company”) (LSE:OXB), the leading gene-based biopharmaceutical company, today publishes its interim management statement for the period from 1 July to 18 November 2013. … Read More